<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362765">
  <stage>Registered</stage>
  <submitdate>16/07/2012</submitdate>
  <approvaldate>16/07/2012</approvaldate>
  <actrnumber>ACTRN12612000757819</actrnumber>
  <trial_identification>
    <studytitle>Ramosetron, low dose midazolam, and their combination for the prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy</studytitle>
    <scientifictitle>In patients undergoing thyroidectomy, which is more effective for the prevention of postoperative nausea and vomiting among ramosetron, low dose midazolam, and their combination?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>postoperative nausea and vomiting in patients undergoing thyroidectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Before induction of anesthesia, ramosetron 0.3 mg combined with low dose midazolam(75 microg/kg) is injected</interventions>
    <comparator>Before induction of anesthesia, ramosetron 0.3 mg or low dose midazolam(75 microg/kg) is injected</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Severity of nausea assessed using 10 point-verbal numerical rating scale(VNRS)</outcome>
      <timepoint>at 0hr, 6hr, 12hr, 24hr postoperatively</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of vomiting</outcome>
      <timepoint>at 0hr, 6hr, 12hr, 24hr postoperatively</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rescue antiemetic recorded by nurse</outcome>
      <timepoint>at 0hr, 6hr, 12hr, 24hr postoperatively</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pain score assessed using 10 point-verbal numerical rating scale(VNRS)</outcome>
      <timepoint>at 0hr, 6hr, 12hr, 24hr postoperatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>fentanyl consumption recorded by nurse</outcome>
      <timepoint>at 0hr, 6hr, 12hr, 24hr postoperatively</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients undergoing thyroidectimy</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>severe impairment of bowel motility, insulin-dependent diabetes mellitus, pregnancy or breast feeding, administration of antiemetic medication within 24 h before operation, history of cardiovascular or respiratory disease, active alcohol or drug usage, obesity (body mass index &gt; 35 kg/m2), impaired renal and/or hepatic function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The details of the series are kept in a set of sealed envelopes, each bearing only the case number on the outside. After admitting into the operating room and just before the induction of anaesthesia, the numbered envelope was opened and the card inside determined which group the patient would be affiliated to.</concealment>
    <sequence>Randomization into one of the three groups was based on Excel random-number generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>69</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Astellas pharma korea, INC.</primarysponsorname>
    <primarysponsoraddress>401 Hakdong-ro, Gangnam-gu Seoul, 135-766</primarysponsoraddress>
    <primarysponsorcountry>Korea, Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Chung-Ang University</fundingname>
      <fundingaddress>224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755</fundingaddress>
      <fundingcountry>Korea, Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing thyroidectomy, The present study was undertaken to compare the effects of ramosetron, low dose midazolam, and their combination on PONV in patients following total thyroidectomy. Patients were randomly assigned to one of three groups to receive antiemetics as follows: ramosetron 0.3 mg, low dose nidazolam 75microg/kg, or their combination. PONV, postoperative pain intensity, rescue antiemetics requirement, and side effects were assessed at 0, 6, 12, 24h postoperatively.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Board of Chung-Ang University School of Medicine</ethicname>
      <ethicaddress>Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea</ethicaddress>
      <ethicapprovaldate>1/06/2012</ethicapprovaldate>
      <hrec>C2012074(769)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Korea, Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hyun Kang</name>
      <address>Department of Anaesthesiology and Pain Medicine Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea</address>
      <phone>+82-2-6299-2571, 2579, 2586</phone>
      <fax>+82-2-6299-2585</fax>
      <email>roman00@naver.com</email>
      <country>Korea, Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Hyun Kang</name>
      <address>Department of Anaesthesiology and Pain Medicine Chung-Ang University College of Medicine 224-1 Heukseok-dong, Dongjak-gu Seoul, 156-755, Korea</address>
      <phone>+82-2-6299-2571, 2579, 2586</phone>
      <fax>+82-2-6299-2585</fax>
      <email>roman00@naver.com</email>
      <country>Korea, Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>